3M™ Tegaderm™ CHGChlorhexidine Gluconate IV Securement DressingsTechnical Brochure

A new lookat IV site protection

3

Intelligent Infection Prevention at IV Sites For

more than 30 years, 3M has been at the forefront of new solutions for

infection prevention. With the innovative Tegaderm™ CHG Dressing, 3M

expands the product portfolio and offers a new look at IV site protection.

The solution is here. The CDC recommends the use

of products containing chlorhexidine gluconate (CHG) as part of a

performance strategy found to be successful in reducing CLA-BSIs.5

3M™ Tegaderm™ CHG Dressings integrate the powerful antimicrobial

effectiveness of CHG with the transparency, reliability and simplicity of a

Tegaderm™ brand dressing to support your best practices and protocols.

One Goal, One Product. Tegaderm™ CHG Dressings are the

only transparent IV site dressings integrated with a CHG gel pad proven to

reduce skin flora, a leading cause of CLA-BSIs ,* on healthy adult subjects.6

2

* 3M™ Tegaderm™ CHG Dressings have not been studied in a randomized clinical study as to their effectiveness in reducing CLA-BSIs.

Proven to Reduce Skin FloraThe Only Transparent CHG IV Site Dressing

4

Reduces Skin Flora

3

Reduces Skin Flora•Proventobeaseffectiveas,orbetterthan,BIOPATCH®atreducingskinflora—aleadingcauseofCLA-BSIs—onhealthyadultsubjectsforupto10days6

•ProventobemoreeffectivethanBIOPATCH®atpreventingregrowthofskinfloraonhealthyadultsubjectsat7days6

•CHGisafast-acting,broad-spectrumantimicrobialandantifungal,showntoprotectagainstavarietyofgram-positiveandgram-negativebacteriaandyeast7,8

Performs Better•ThemajorityofcliniciansratedTegaderm™CHGDressingsbetterthanBIOPATCH®inoverallperformance9

•Gelpadconformstobodycontours,flexeswithpatientmovementandsupportsvariedinsertionpractices

•Transparentdressingisbreathable,allowinggoodmoisturevapourexchange•3Madhesivetechnologyprovidesbetteradherenceforlongerweartimeandlessstressonskin

Protects Better•Unique,adhesivegelpadconformsaroundcatheterandhubforbettersecurement•TransparentfilmintegratedwithCHGservesasabarriertoorganisms,includingthosemostcommonlyassociatedwithCLA-BSIs5,10

•CHGisimmediatelyactiveandcontinuouslyavailablefromthegelpadforpersistentprotection11

Supports Best Practices and Protocols •Transparent,allowingcontinuoussiteobservation,asrecommendedbyboththeCentersforDiseaseControlandPrevention(CDC)andtheInfusion Nursing Standards of Practice5,12

•Integrated,one-stepCHGandtransparentdressinghelpstoimprovecompliancetofacilityprotocol

•Intuitivedesignisclinician-friendlyandease-of-applicationminimizesopportunityforerror

•CHGantimicrobialcannotbeappliedincorrectlyorforgotten

Proven to Reduce Skin FloraThe Only Transparent CHG IV Site Dressing

5

Infection: A Major Health Care ConcernInfectionpreventionremainsoneofmedicine’smostpersistentchallenges.Whileimprovedhealthcarehasdrivendownthenumberofdeathsattributabletosomeofthemostdreadeddiseases,healthcare-acquiredinfections(HAIs)remainhighandareamajorpublichealthconcern.

IVs: An Access Point for MicrobesWhileintravascularcathetersareanecessarycomponentofthecontinuumofcare,theinsertionsiteofcathetersprovidesanaccesspointforpathogenstoenterthebody,placingthepatientatriskforlocalandsystemicinfectiouscomplications.Studieshaveshownthatbetween5%and25%ofIVdevicesarecolonizedatthetimeofremoval.16Themostcommonsourcesofcathetercolonizationaretheskinsurface,thecatheterhubandthecathetersurface.SeeFigure1.

CoSt to tHe patient CoSt to tHe faCility

•14,000–28,000patientdeathsannually attributed to CLA-BSIs16

•Extendedhospitalstays— 18 days17

•ExtendeddaysintheICU

•Financialimpactonfamilies

•Increasedhealthcomplications

•Decreasedabilitytoworkorperform daily activities

•$34,508–$56,000—estimated cost per bloodstream infection3,18

The Cost is Too HighTheCDCestimatesthat80,000CLA-BSIsoccureachyearinICUs,whilemoresignificantly,250,000casesofCLA-BSIsoccurannuallyifentirehospitalsareassessed.5

figuRe 1: iV inSeRtion Site — an aCCeSS point foR MiCRobeS

4

SKIN

CATHETER HUB

ANTIMICROBIAL CHG GEL

HOW DO TEGADERM™ CHG DRESSINGS BREATHE?

ACCESS POINT FOR MICROBES

SKIN

TEGADERM™ FILM

FLUIDS

BACTERIA

BACTERIA

VIRUSES*

WATER

OXYGEN

WATER VAPOUR + CO2

VEIN CATHETER SURFACE

VIRUSES

The density of skin flora at the catheter insertion site is a major risk factor for CLA-BSIs, and it is estimated that up to 60% of CLA-BSIs originate from the patient’s own skin.5,13-15

6

A Bundled Approach to Improving OutcomesHealthcarefacilitiesarelookingforevidence-basedpracticestoreduceinfectionratesandcontributetoimprovedoutcomes.The2011CentersforDiseaseControlandPrevention/HICPACGuidelines for the Prevention of Intravascular Catheter-Related Infectionsrecommendstransparentdressingsbecausethey“…permitcontinuousvisualinspectionofthecathetersiteandrequirelessfrequentchangesthandostandardgauzeandtapedressings.”5

TheCDCGuidelinesforthePreventionofIntravascularCatheter-relatedInfections(2011)recommendchlorhexidinegluconate(CHG)antisepticovertinctureofiodine,idophorsoralochol.5Inuseforover50years,CHGhasproventobeaveryeffectiveantimicrobialthatisminimallyaffectedbythepresenceoforganicmatter(includingblood)andhasagoodsafetyrecordwhenusedasdirected.AllergicreactionstoCHGareuncommon(WHO,2009).19

CHain of eVentS leading to Cla-bSis

CHG skin preps help to reduce skin flora, however, the flora will rebound with time.

Skin flora counts will remain high on some patients, even after prepping.

Catheter insertion sites with higher bacterial counts are more likely to lead to CLA-BSIs.

The patient’s skin flora is the most common source of catheter colonization.

Migration of skin organisms on to the catheter is the most common route of infection.

Maintaining low bacterial counts on the skin helps to reduce the incidence of CLA-BSIs.

Tegaderm™ CHG Dressings have been proven to maintain low bacterial counts for up to 10 days.

Reducing Skin Flora is Key

3M™ Tegaderm™ CHG Dressings have not been studied in a randomized clinical study as to their effectiveness in preventing CLA-BSIs.

5

The gel pad conforms and adheres to the catheter and skin, maintaining intimate contact between the CHG and skin.

7

Integrated CHG Technology for Infection Prevention

Tegaderm™CHGDressingsaretheonlytransparentdressingsintegratedwithaCHGgelpadofferinginfectionpreventionistsandhealthcareprofessionalsallthebenefitsofCHGprotectionandtransparentdressinginoneproduct.

Continuous Antimicrobial ActivityUnlikeoldertechnologiesthatdriedCHGonaspongedisk,Tegaderm™CHGDressingshaveCHGdissolvedintoasoftgelpadwhichbathestheinsertionsiteinCHG,allowingtheCHGtomigrateunderthecatheterandprovidingalargerzoneofinhibition.Thisreservoirofantisepticprovidesconsistent,continuouscoverageovertime.Becauseofitsaqueouscomposition,theCHGisavailableinsolutionformandwillbegintoattackskinfloraimmediatelyuponapplication.11Thegelpaddoesnotrequiremoisturetoactivate,soevendrysiteswillreceiveantimicrobialbenefit.

Catheter SecurementInaddition,thegelpadconformsandadherestothecatheterandskin,helpingtomaintainintimatecontactbetweentheCHGandskinandimprovecathetersecurement.Thegelpadalsoabsorbsavarietyoffluidsincludingblood,salineandexudateandcouldbecomeanalternativetogauzeandtapeformanyinitialcatheterinsertions.9,10,20

Barrier ProtectionIn vitrotestingshowsthatthetransparentfilmofTegaderm™CHGDressingsprovidesaviralbarrierfromviruses27nmindiameterorlargerwhilethedressingremainsintactwithoutleakage.

figuRe 2: CoMpoSition of tegadeRM™ CHg gel padCOMPOSITION OF TEGADERM™ CHG GEL PAD

CHG HAS BEEN DISSOLVED INTO A SOFT GEL MADE FROM WATER, POLYMERS, POLYOL AND 2% CHLORHEXIDINE GLUCONATE AND INTEGRATED INTO A TRANSPARENT DRESSING.

POLYMER

WATER

CHG

POLYOL

The CHG gel pad is made from water, polymers, polyol and 2% chlorhexidine gluconate and integrated with a transparent dressing.

Smaller size: Tegaderm™ CHG Dressing 1660R provides catheter securement to meet all your patient needs.

6

8

tegaderm™ transparent film

•Servesasabarriertoorganisms, including those most commonly associated with CLA-BSIs

•Allowscontinuoussiteobservation

•Conformstobodycontours,flexeswithpatient movement and supports varied insertion practices

•Semipermeable,breathable,allowsgoodmoisture vapour exchange

CHg gel pad

•Uniquecompositionofwater,polymersand 2% chlorhexidine gluconate

•CHGisimmediatelyandcontinuouslyavailable,doesnotrequireadditionalmoisture

•TheabsorptiveCHGgelpadprotectseven in the presence of blood, saline and exudate

Sterile tape Strips

•Precutforanchoringhubs,lumens or tubing

•Versatileandeasytoapply

•Includespreprintedlabelsfor documenting dressing changes

Catheter Securement

•Gelpadconformsaroundcatheter,helpingprovidecatheter securement

•AdhesiveCHGgelpadconformsaroundcatheter and hub

•Uniquedressingdesignwithdeepnotchhelps reduce dressing lift caused by the weight of the catheter and tubing

Site VisibilityThetransparentfilmallowscontinuoussiteobservation,astandardpracticeforIVnursesandclinicians.

Tegaderm™CHGDressingsadvancecurrentIVsiteprotectioneffortsbyintegratingtheantimicrobialpowerofCHG,withaneasy-to-applyadhesivetransparentfilmdressing.

7

Soft Cloth border

•Reinforcedbordersandnotcheshelptoreduce edge lift and create a better seal around the catheter

•Providescomfortanddurability

•Intuitivedesignisclinician-friendly, ease-of-application minimizes opportunity for error

9

Proven Antimicrobial EffectivenessTegaderm™CHGDressingsprovidecontinuousantimicrobialprotection.Extensivein vivoandin vitrotestingwascompletedtoevaluatetheirperformanceandeffectivenessinreducingskinflora.Tegaderm™CHGDressings:6,10,21

• Killskinflora• Provideprogressive“kill”overtime• Providebroad-spectrumactivity• OfferthesamelevelofantimicrobialactivityatDay10asDay1

• Continuetobeeffectiveinthepresenceofblood,salineandexudate

Reduces Skin FloraThisin vivotime-killstudywasdesignedtochallengeCHG-impregnateddressingsontheunpreppedskinofhealthyadultsubjects.Unpreppedskinprovidedhighlevelsofmixedbacterialpopulationsthatcannormallybefoundonhumanskin.Tegaderm™CHGDressingswereshowntobemoreeffectivethanBIOPATCH®andtransparentfilmdressingsatreducingskinfloraonhealthysubjectsforupto10days.Tegaderm™CHGDressingswerealsosignificantlybetterthanBIOPATCH®inprovidingprogressivekillofthemicrofloraonthetestsubjectsacrossalltimepoints(Days1,2,4,7and10).6SeeFigure3.

Suppresses RegrowthTegaderm™CHGDressingsprovideareservoirofCHGforcontinuousantimicrobialactivityovertime.Inthisstudy,usingalcoholastheskinantiseptic,Tegaderm™CHGDressingsdemonstratedtheirabilitytomaintainbacteriallogcountslowerthantheaveragepost-prepcountforupto10days.6SeeFigure4.

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

0 1 2 3 4 5 6 7 8 9 10

DAYS

BIOPATCH® 3M™ TEGADERM™

CHG DRESSING

LOG

CFU/

CM2 ±

SEM

figuRe 3: in vivo tiMe kill of floRa6

3M™ TEGADERM™

CHG DRESSING3M™ TEGADERM™

DRESSING (CONTROL) BIOPATCH®

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

BASELINE POST-PREP DAY 7 DAY 10

LOG

CFU/

CM2 ±

SEM

BASELINE SKIN FLORA

POST-PREPCOUNT

figuRe 4: SuppReSSion of RegRoWtH6

Suppression of regrowth on prepped subclavian sites with the two CHG-impregnated dressings on healthy adult volunteers. At day 7, the new integrated CHG transparent dressing showed significantly lower regrowth post prep compared to the control (p<0.0001). At day 10, both CHG dressings showed significantly lower regrowth (p<0.0003). There was a statistically significant difference between the new integrated CHG-impregnated transparent dressing and the CHG-impregnated sponge dressing at day 7 (log10 cfu 0.80, P<0.02).

In vivo time kill of normal flora on unprepped skin with the two CHG-impregnated dressings on healthy adult volunteers. The likelihood-based repeated measures analysis, which included both dressing and time in the model, showed the new integrated CHG-impregnated transparent dressing to be significantly more effective than the CHG-impregnated sponge dressing in reducing floral counts on unprepped skin across all time points (P+0.008).

8

10

DAY1 102 3 4 5 6 7 8 9

0.0

2.0

4.0

6.0

8.0

10.0

12.0

TEGADERM™ CHG IS AS AVAILABLE AND EFFECTIVE AT DAY 10 AS DAY 1.

3M™ TEGADERM™ CHG GEL PAD

CONTINUOUS PROTECTION OVER TIME

ZON

E O

F IN

HIBI

TIO

N B

EYO

ND

GEL

PAD

(MM

)

figuRe 6: ContinuouS pRoteCtion oVeR tiMe11

Works with CHG Skin PrepWhileCHGskinprepsprovideeffectivetemporaryreductionofskinflora,CHGisacationicmoleculeandwillbecomeinactiveovertimeifexposedtoanionicmaterialsontheskin.8Ongoingexposuretotheantisepticisneededtomaintainlowskinfloracounts.Inonestudy,using2%CHG /70%alcoholastheskinantiseptic,Tegaderm™CHGDressingsmaintainedsignificantlylowercountsthanBIOPATCH®orcontroldressingsafter7daysonhealthyadultsubjects.21SeeFigure5.

Provides Continuous ProtectionIn vitrotestsdemonstratetheavailabilityandsustainedreleaseovera10-dayperiod.Inthisstudy,thesameTegaderm™CHGgelpadwastransferreddailyontoanagarspreadwith4to5logsofbacteria.ThereservoirofCHGwithinthegelpadwasasavailableandaseffectiveatDay10asDay1.11SeeFigure6.

Effective Against Most Common Pathogens Causing CLA-BSIsIn vitrotestingshowsTegaderm™CHGDressingshavebroad-spectrumactivityagainst,andareabarrierto,awidespectrumofgram-positiveandgram-negativebacteriaandyeast.10Theseincludethepathogensthatareofmostconcerntoepidemiologistsandinfectionpreventionists.22SeeFigure7.

9

3M™ TEGADERM™ DRESSING (CONTROL)

3M™ TEGADERM™ CHG DRESSING

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

N=31 31 31 31 31 30 30 30 30 29 30BASELINE POST-PREP DAY 1 DAY 4 DAY 7

ADD FOOTNOTES FOR * + **

MEA

N LO

G CO

UNT

LOG 10

CFU

/CM

2

BIOPATCH®

****

**

*

figuRe 5: MaintainS loW Skin CountS21

figuRe 7: MoSt CoMMon patHogenS CauSing Cla-bSis5MOST COMMON PATHOGENS CAUSING CRBSI

ADD FOOTNOTECDC. GUIDELINES…

37%

14%13%

17%

5%

5%

4%

3%

2% COAG NEG STAPHENTEROCOCCUSS. AUREUSCANDIDAENTEROBACTERPSEUDOMONASKLEBSIELLAE. COLIOTHER

11

figuRe 8: gRaM poSitiVe22

figuRe 9: gRaM negatiVe & yeaSt22

Greater Zone of Antimicrobial ActivityTheTegaderm™CHGgelpad’suniquesize,shapeandcompositionprovidesagreaterzoneofantimicrobialactivitythanBIOPATCH®.11Thelargergelpadsurfaceareaallowsforcoverageofsuturesaswellastheinsertionsite.SeeFigures8and9.

CHG Migrates Under the CatheterTegaderm™CHGDressingsplacedoveracathetersiteprovidecontinuousantimicrobialprotectionwithoutexcessivemanipulationorintrusionunderthecatheter.23Usingthematrix-assistedlaserdesorption/ionization(MALDI)technique,researcherswereabletodemonstratethepresenceofCHGinveryfineincrementallocationsontheskinfromtheTegaderm™CHGDressings.Moreover, skin recovered from under the catheters also showed the presence of CHG in 24 hours.Tegaderm™CHGDressingsprovidedCHGlevelsontheskinthatincreasedwithtime,reachingasteadystateaftertwodays.23SeeFigure10.

1 2 4 7STUDY DAYS

% C

HG R

ECOV

ERY

-10

0

10

20

30

40

50

60

70

80

90

% CHG UNDER CATHETERfiguRe 10: CHg undeR CatHeteR23

GRAM POSITIVE – ZOI

Staphylococcus epidermidis 13518Staphylococcus epidermidis 49461

Staphylococcus epidermidis 49134

Staphylococcus epidermidis 14990

Staphylococcus epidermidis (MRSE) 51625

Staphylococcus epidermidis (MRSE) nasal isolate #492

Staphylococcus aureus 25923

Staphylococcus aureus (MRSA/GRSA) 33592

Staphylococcus aureus (MRSA) USA 100

Staphylococcus aureus (MRSA) USA 300

Staphylococcus aureus(MRSA) USA 600

Staphylococcus aureus(MRSA) USA 500

Staphylococcus aureus(MRSA) USA 800

Staphylococcus aureusNasal Isolate #849

Staphylococcusfaecium (VRE) 700221

Staphylococcusfaecium (MDR) 51559

Staphylococcusfaecalis 7080

Staphylococcusfaecalis 19433

Staphylococcus faecalisWound Isolate #23

Corynebacterium diphtheriae 13812Staphylococcus epidermidis 1228

60

50

40

30

20

10

AVERAGE ZONE GEL DIAMETER (24 MM)

GRAM NEGATIVE & YEAST – ZOI

40

35

30

25

20

15

10

5

Acinetobacter baumannii BAA-747

Acinetobacter baumannii BAA-747

Pseudomonas aeruginosa 10145

Pseudomonas aeruginosa 10662

Pseudomonas aeruginosa 35032

Pseudomonas aeruginosa 9027

Pseudomonas aeruginosa 27853Enterobacter cloacae 35549

Klebsiella pneumoniae 13883

Klebsiella pneumoniae 23357

Escherichia coli 25922

Proteus mirabilis 12453

Proteus mirabilis 7002

Candida albicans 10231

Candida albicans 58716

Acinetobacter baumannii 19606

AVERAGE ZONE GEL DIAMETER (24 MM)

10

12

Supports Best PracticesTegaderm™CHGDressingssupportthegoalsofprofessionalstandards,guidelinesandfacilityprotocolsforimprovingpatientoutcomes.

Supports Professional Standards & Guidelines• TheCDC/HICPACGuidelines for the Prevention of

Intravascular Catheter-Related Infectionsrecommendsusingtransparentfilmdressings5

• TheInfusion Nursing Standards of PracticerecommendsthatasteriledressingbeappliedandmaintainedtoprovideprotectionoftheIVsite12

Improves Compliance to Facility ProtocolResearchhasshownTegaderm™CHGDressingsareeasytouseandfitintoclinicalpracticeaseasilyasothertransparentdressings.24,25

Theintuitivedesignisclinician-friendlyandtheease-of-applicationminimizesopportunityforerror.Theintegrated,one-stepCHGandtransparentdressinghelpstoimprovecompliancetofacilityprotocol.Thereisnoquestionabouthowtoapplythem.TheCHGantimicrobialcannotbeappliedincorrectlyorforgotten.Thegelpadconformstothecatheterandcoverstheinsertionsite,providingCHGwhereitisneededmost.

11

13

MUCH BETTER OR BETTER

SAME AS MUCH WORSEOR WORSE

81%

10% 10%

0%

10%

20%

30%

40%

50%

60%

90%

70%

80%

OVERALL PERFORMANCE OF THE INTEGRATED TRANSPARENT CHG GEL DRESSING

figuRe 12: oVeRall peRfoRManCe 3M™ tegadeRM™ CHg dReSSing VeRSuS biopatCH®27

3M Kept it SimpleAspartofaclinicalevaluation,cliniciansweretrainedinproperTegaderm™CHGDressingandBIOPATCH®applicationandremovaltechniquesandaskedtoapplythedressingsimmediatelyaftertraining.Tegaderm™CHGDressingsratedsignificantlyeasiertoapplycomparedtoBIOPATCH®withtransparentcoverdressing.26

Tegaderm™CHGDressingsratedsignificantlybettercomparedtoBIOPATCH®in:• Overallperformance• Easeofcorrectapplication• AbilitytoseetheIVsite• Easeoftraininganotherclinician• Moreintuitivetouse

Preferred by CliniciansInseparateclinicalevaluations,cliniciansratedTegaderm™CHGDressingssignificantlyeasiertoapplythanBIOPATCH®.ExperiencedBIOPATCH®usersevaluatedfitwiththeirexistingclinicalpracticeand81%ratedTegaderm™CHGDressingsasbetterormuchbetterthanBIOPATCH®.SeeFigure12.AmajorityrecommendedaswitchtoTegaderm™CHGDressingsovertheBIOPATCH®plustransparentfilmdressingforPICClines,IJinsertionsites,andnon-tunneledCVC-subclavianinsertionsites.9,27

12

figuRe 11: 3M™ tegadeRM™ CHg dReSSingS MiniMize appliCation eRRoRS26

In clinical practice, the BIOPATCH® disk is often laid on top of the catheter at the insertion site, greatly diminishing its efficacy.6

100%

83.3%

66.7%

91%

CORRECT INTERNAL JUGULAR APPLICATIONS

CORRECT PICC APPLICATIONS

3M™ TEGADERM™ CHG DRESSING BIOPATCH®

14

Tegaderm™ CHG Dressings are gentle on the skin.

All the Benefits of a Trusted Tegaderm™ Brand DressingFormorethan25years,Tegaderm™brandtransparentdressingshaveassistedcliniciansinprovidingoptimalIVsitecareandhavebecomeapopularmeansofdressingcatheterinsertionsites.• Gentle adhesive –Tegaderm™CHGDressingsaremadewiththesamelatex-freeadhesiveasstandardTegaderm™branddressingswhichprovidesthestrengthtosecurelyholdcathetersinplace,yetisgentletotheskin.

• Conformable–Tegaderm™CHGDressingsconformtocontoursofthebodyandpreventstressontheskinwhenthepatientmoves.

• Breathable–Tegaderm™CHGDressingspermitvapourandoxygenexchangethroughthesemipermeablepolyurethanefilm.SeeFigure13.

• Fits into the continuum of care–Tegaderm™CHGDressingsareradiologicallytransparentandcompatiblewithCT(computerizedtomography)andMRI(magneticresonanceimaging).

• Waterproof, sterile barrier–Tegaderm™TransparentDressingsarebreathable,semipermeablefilmsormembranesthatprovideabarriertoexternalcontaminantsincludingliquids,bacteriaandyeast.SeeFigure13.

Plus...• Antimicrobial–TheCHGgelpadprovidescontinuousantimicrobialprotectionagainstmicroorganisms,includingthosemostcommonlyassociatedwithCLA-BSIs.

• Absorbs fluid–TheabsorptiveCHGgelpadprovidesprotectioneveninthepresenceofblood,salineandexudate.

• Securement–AdhesiveCHGgelpadconformsaroundcatheterandhub.

SKIN

CATHETER HUB

ANTIMICROBIAL CHG GEL

HOW DO TEGADERM™ CHG DRESSINGS BREATHE?

ACCESS POINT FOR MICROBES

SKIN

TEGADERM™ FILM

FLUIDS

BACTERIA

BACTERIA

VIRUSES*

WATER

OXYGEN

WATER VAPOUR + CO2

VEIN CATHETER SURFACE

VIRUSES

figuRe 13: HoW tegadeRM™ dReSSingS bReatHe

13

15

Supporting Your Infection Prevention Efforts3Mhelpsyoudelivertangible,positiveresults—bybringingthebroadestarrayofsolutionstothefightagainsthospital-acquiredinfections.

• Arecognizedleaderinresearchanddevelopment,3Mhasbeenprovidinghealthcareprofessionalsandpatientswithinnovativesolutionsthathelpmakepeople’slivesbetter,since1948.

• 3Mdeliverstheresourcesyouneedtobealeaderindetecting,preventingandcontrollinghospital-acquiredinfectionsandaccesstokeyopinionleaderswhocanhelpclinicalmanagersunderstandandleadthroughthesechanges.

• Evidence-basedsolutions.Customersexpectitand3Miscommittedtocontinuouslyexpandtheextensivebodyofclinicalevidencethatsupportstheeffectivenessof3Mproductsandsolutions.

• 3Misatrustworthy,crediblepartnerforhospitals—dedicatedtohelpinghospitalsdotherightthingfortheirbusinessandtheirpatients.

14

3M™ Tegaderm™ CHG Dressings come in multiple sizes and shapes for a variety of catheter sites (photos showing subclavian site, internal jugular, peripherally inserted central catheter and arterial line). Not intended to replace sutures on non-tunneled catheters.

References1 SafdarN,MakiDG.Riskofcatheter-relatedbloodstreaminfectionwithperipherally

insertedcentralvenouscathetersusedinhospitalizedpatients.Chest2005;128(2):489-95.

2 Mermel,LA,McCormick,RD,Springman,SR,&Maki,DG(1991).Thepathogenesisandepidemiologyofcatheter-relatedinfectionwithpulmonaryarterySwan-Ganzcatheters:Aprospectivestudyutilizingmolecularsub-typing.American Journal of Medicine.91;197S-205S.

3 DimickJB,PelzRK,ConsunjiR,SwobodaSM,HendrixCW,LipsettPA.Increasedresourceuseassociatedwithcatheter-relatedbloodstreaminfectioninthesurgicalintensivecareunit.Arch Surg.2001;136:229–34.

4 MermelLA.Correction:catheter-relatedbloodstream-infections.Ann Intern Med.2000;133:395.

5 CentersforDiseaseControlandPrevention.Guidelinesforthepreventionofintravascularcatheter-relatedinfections,2011.

6 MakiDG(2008),etal.ANovelIntegratedChlorhexidine-ImpregnatedTransparentDressingforPreventionofVascularCatheter-relatedBloodstreamInfection:AProspectiveComparativeStudyInHealthyVolunteers.SHEA,April2008.

7 Milstone,AM,PassarettiCL,PerlTM.Chlorhexidine:expandingthearmamentariumforinfectioncontrolandprevention.Clin Infect Dis.January15,2008;46:274-281.

8 DentonGW.Chlorhexidine.Takenfrom:BlockSS,ed.Disinfection, Sterilization, and Preservation.5thed.Philadelphia,PA:Lippincott,Williams&Wilkins;2001;321-336.

9 DeschneauM(2008),etal.AMulticenterprospectiveopenlabelevaluationoftheclinicalperformanceofachlorhexidinegluconateantimicrobialtransparentdressing.InfusionNursesSociety(INS),May2008.

10 In vivo, in vitro3Mdataonfile.11 SchwabD(2008),etal.AntimicrobialActivityofaCHG-ImpregnatedGelPadforIV

SiteProtection.InfusionNursesSociety(INS),May2008.12 InfusionNursingStandardsofPracticeSupplementtoJan/Feb2011Vol34,1SISSN

1533-1458.13 RyderM.Evidence-basedpracticeinthemanagementofvascularaccessdevicesfor

homeparenteralnutritiontherapy.Parenter Enteral Nutr (JPEN).January-February2006;30:S82-S93.

14 SafdarN,MakiDG.Thepathogenesisofcatheter-relatedbloodstreaminfectionwithnoncuffedshort-termcentralvenouscatheters.Intensive Care Med.January2004;30(1):62-67.

15 ElliottTSJ,MossHA,TebbsSE,etal.Novelapproachtoinvestigateasourceofmicrobialcontaminationofcentralvenouscatheters.Eur J Clin Microbiol Infect Dis.March1997;16(3):210-213.

16 MakiDG,MermelLA.Infectionsduetoinfusiontherapy.Takenfrom:BennettJV,BrachmanPS,eds.Hospital Infections.Philadelphia,PA:Lippincott-Raven;1998;689-724.

17 MurphyD,WhitingJ,HollenbeakCS.Dispellingthemyths:thetruecostofhealthcare-associatedinfections.Healthcare Financial Manage.March2007.

18 RelloJ,OchagaviaA,SabanesE,etal.Evaluationofoutcomeofintravenouscatheter-relatedinfectionsincriticallyillpatients.Am J Respir Crit Care Med.2000;162:1027–30.

19 WorldHealthOrganization.GuidelinesonHandHygieneinHealthCare:FullDocument,2009.

20 Olson,C(2009).TheAbsorptiveAbilitiesofaCHGGelDressing:CanInitialGauzeDressingsbeAvoided.SHEA,Mar2009.

21 Bashir,MH(2008),etal.SuppressionofRegrowthofNormalSkinFloraunderChlorhexidineGluconateDressingsAppliedtoCHG-PreppedSkin.ICAAC/IDSA,Oct2008.

22 HenslerJ(2009),etal.GrowthinhibitionofmicroorganismsinvolvedinCA-infectionsbyanantimicrobialtransparentIVdressingcontainingCHG.EuropeanSocietyofClinicalMicrobiologyandInfectiousDiseases,May2009.

23 SchwabD(2008),etal.MigrationofChlorhexidineGluconateUnderAntimicrobialGelPadofIVSecurementDressingtoProvideContinualAntimicrobialProtection.AssociationforVascularAccess(AVA),Sept.2008.

24 OlsonC(2008).ClinicalPerformanceofaNewTransparentChlorhexidineGluconateCentralVenousCatheterDressing.Journal of the Association for Vascular Access (JAVA).March2008;Vol13No.113-19.

25 RuppME(2008),etal.Prospective,Randomized,ControlledTrialAssessingtheClinicalPerformanceofaTransparentChlorhexidineGelPadIntravascularCatheterDressing.SHEA,April2008.

26 EybergC(2008),etal.AControlledRandomizedProspectiveComparativeStudytoEvaluatetheEaseofUseofaTransparentChlorhexidineImpregnatedGelDressingVersusAChlorhexidineDiskinHealthyVolunteers. Journal of the Association for Vascular Access (JAVA),Fall2008Vol.13No3.

27 ZehrerC(2009),etal.ProductevaluationofanewCHGdressingforcathetercare.InfusionNursesSociety(INS),May2009.

3M also provides:• Experiencedsalesandsupportteam,specializedintheareasofinfectionpreventionandIVsiteprotection

• Clinicalandtechnicalspecialistswhoprovidesupportusingavarietyofmethods–In-servicetraining,professionalcontinuingeducationandconversionprograms

–Protocoldevelopmenttopromoteclinicaloutcomes,standardizationandutilizationwithinyourdepartments

• Toll-freehelplinethatoffersexpertstoassistcustomerswithtechnicalandproductinformation

VisitourWebsitetoaccesstheTegaderm™CHGDressingInteractiveIn-serviceatwww.3M.com/tegadermchg.

For more information, visit www.3M.com/tegadermchg, contact your 3M Skin & Wound Care Representative,

or call the 3M Health Care Customer Helpline at 1-800-364-3577. These products can be ordered from your local distributor.

1657R 1659R 1660R

CATALOGUE NUMBER

PRODUCT SIZE

GEL PAD SIZE

SAME SIZE/SHAPE AS TEGADERM™ DRESSING PACKAGING

1657R3 1/2 in x 4 1/2 in8,5 cm x 11,5 cm

1 1/2 in x 1 3/8 in3 cm x 4 cm

1655 25 dressings/box4 boxes/case

1659R4 in x 6 1/8 in

10 cm x 15.5 cm1 1/2 in x 2 4/5 in

3 cm x 7 cm1650 25 dressings/box

4 boxes/case

1660R2 3/4 in x 3 3/8 in

7 cm x 8,5 cm4/5 in x 4/5 in 2 cm x 2 cm

— 25 dressings/box4 boxes/case

Product and package are latex free.

Ordering Information:

3M Health Care 3M Centre, Building 275-4W-02 St. Paul, MN 55144-1000 U.S.A.

Please recycle. Printed in Canada.3M and Tegaderm are trademarks of 3M. Used under license in Canada.© 2011, 3M. All rights reserved.1106-02094E BIOPATCH is a registered trademark of ETHICON, INC.

Available in Canada from:Skin & Wound Care3M Canada CompanyP.O. Box 5757London, Ontario N6A 4T1Canada1 800-364-3577www.3M.ca/healthcare